UBS Goes Bullish on ALXO: Buy Rating Highlights Evorpacept's Breast Cancer Promise

UBS starts coverage on ALX Oncology (ALXO) with a Buy rating and $6 price target, highlighting the potential of its CD47 blocker evorpacept in metastatic breast cancer.